Feb
24
2022
On demand

Introducing Lonza’s AAV suspension transient transfection platform to de-risk your path to clinic

Adeno associated viral vector (AAV) is the delivery vehicle of choice for potentially curative in vivo gene therapy. Following a couple of landmark approvals, this field has experienced accelerated pipeline growth and investor interest in the past five years. Currently AAV therapies are predominantly targeting rare genetic disorders for which the patient population is often limited. As a result, drug developers feel immense pressure to be first to market to commercialize their therapies. 

In this Webinar, Lonza CGT will focus on a robust, streamlined platform process for fast production of AAV using Lonza’s clonal suspension HEK293 cell line, proprietary plasmids to ensure high productivity and in process analytics enabling enhanced full to empty capsid ratio. We will further discuss Lonza’s approach for building reliable, de-risked path to clinic to avoid unforeseen costs and compliance-related delays.

  • Speed to clinic with a de-risked, robust, scalable platform process for AAV production
  • High AAV productivity and yield with Lonza’s proprietary plasmids (Rep/cap + pHelper) and clonal HEK293 cell line
  • Full/empty analytics enabling USP and DSP optimization at early stages/small scale
  • Pre-qualified platform assays

Dr Suparna Sanyal

Head of Viral Vectors Commercial Development, Lonza Pharma & Biotech

Dr Suparna Sanyal is Head of Viral Vectors Commercial Development at Lonza Cell and Gene Technologies where she works with their global business, R&D and operations teams to enable strategic development and commercialization of their viral vector manufacturing services. Suparna’s background is in Neuroscience and she earned her PhD from the University of Toronto in Neuropharmacology. She has over 15 years of R&D, drug discovery, CDMO and cell and gene therapy experience.


SPEAKERS

Suparna Sanyal
Head of Viral Vectors Commercial Development at Lonza Pharma & Biotech

You might also like

Accelerating cell therapy discovery & development with non-viral gene...

D Hermanson
X Patrinostro
David Hermanson
David Hermanson
Senior Manager of R&D Applications, Cell and Gene Therapy at Bio-techne
Xiaobai Patrinostro
Xiaobai Patrinostro
Manager of Genome Engineering Services, Cell and Gene Therapy at Bio-techne
16 Jun 2022
29
Days
15
Hrs
17
Min
Register

Applying an HPLC analytical platform for mRNA process monitoring

N Pavlin
Nejc Pavlin
Nejc Pavlin
Project Manager in Process Analytics Development at BIA Separations
7 Jun 2022
21
Days
7
Hrs
17
Min
Register

Optimizing E. Coli cell growth performance with in-line, real-time OD600...

T Buch
R Shanbaky
Tanja Buch
Tanja Buch
Technical Director at Biifactory Competence Center
Ramsey  Shanbaky
Ramsey Shanbaky
Bioprocess Applications Manger at C Technologies, Inc - a Repligen Company
1 Jun 2022
14
Days
15
Hrs
17
Min
Register

Manufacturing considerations for viral and non-viral platform selection

V Slepushkin,
A Noyes,
A Hagerman et al.
Vladimir Slepushkin
Vladimir Slepushkin
Global Head of Manufacturing at MedTherapy Biotech
Aaron Noyes
Aaron Noyes
Vice President of Development at Codiak Biosciences
Allison Hagerman
Allison Hagerman
Vice President, Product Development, Oncolytics Biotech
Laurens  Sierkstra
Laurens Sierkstra
Senior Director, Business Leader, Purification at Thermo Fisher Scientific
10 May 2022
Watch now

From cells to purified capsids: How to develop a scalable rAAV process

Å Hagner McWhirter
Åsa Hagner McWhirter
Åsa Hagner McWhirter
Principal Scientist at Cytiva
3 May 2022
Watch now